Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Candriam S.C.A.

Candriam S.C.A. cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 37.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 303,972 shares of the company’s stock after selling 179,269 shares during the period. Candriam S.C.A. owned 0.30% of Neurocrine Biosciences worth $41,492,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NBIX. Robeco Institutional Asset Management B.V. increased its holdings in shares of Neurocrine Biosciences by 16.0% during the third quarter. Robeco Institutional Asset Management B.V. now owns 387,282 shares of the company’s stock valued at $44,623,000 after purchasing an additional 53,301 shares during the period. Asset Management One Co. Ltd. increased its holdings in shares of Neurocrine Biosciences by 2.5% during the third quarter. Asset Management One Co. Ltd. now owns 69,230 shares of the company’s stock valued at $7,977,000 after purchasing an additional 1,705 shares during the period. QRG Capital Management Inc. increased its holdings in shares of Neurocrine Biosciences by 3.2% during the third quarter. QRG Capital Management Inc. now owns 18,279 shares of the company’s stock valued at $2,106,000 after purchasing an additional 569 shares during the period. Impax Asset Management Group plc increased its holdings in shares of Neurocrine Biosciences by 70.0% during the third quarter. Impax Asset Management Group plc now owns 85,000 shares of the company’s stock valued at $9,794,000 after purchasing an additional 35,000 shares during the period. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of Neurocrine Biosciences during the third quarter valued at $3,588,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Up 0.7 %

NASDAQ:NBIX opened at $113.85 on Thursday. The company has a fifty day moving average of $133.53 and a 200-day moving average of $127.70. The firm has a market capitalization of $11.35 billion, a P/E ratio of 34.60, a P/E/G ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences, Inc. has a twelve month low of $110.25 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has authorized a share buyback program on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

NBIX has been the subject of several research reports. Bank of America decreased their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Barclays raised their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a “hold” rating and a $138.00 target price on the stock. Wedbush decreased their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada decreased their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $166.90.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the transaction, the director now directly owns 517,030 shares of the company’s stock, valued at $79,064,227.60. The trade was a 0.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now directly owns 2,507 shares in the company, valued at $346,216.70. This trade represents a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 234,269 shares of company stock worth $34,053,879. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.